Brazil · Business
Key Facts
—CADE Recommendation On July 23, 2026, CADE’s Superintendence recommended condemning Bayer, Monsanto, and related entities for anti-competitive practices in Brazil’s soybean seed market.
—Alleged Practices The case centers on incentives for plant breeders to adopt Intacta RR2 PRO and non-linear loyalty discounts in Monsanto’s Monsoy Multiplica program.
—Not Final The recommendation is not a final ruling. The Tribunal of CADE must still decide the case, meaning the process remains ongoing.
—Royalty Dispute Brazilian farmers’ group Aprosoja-MT claims Bayer owes roughly R$10 billion (~US$1.96 billion) in royalties, while Bayer rejects a separate US$2 billion liability claim.
—New Inquiry The authority also recommended opening a new administrative inquiry into incentives linked to Intacta 2 Xtend and Xtend technologies.
CADE Bayer Monsanto tensions escalated sharply on July 23, 2026, when the Superintendence of Brazil’s antitrust regulator recommended the condemnation and fining of Bayer, Monsanto, and related entities for alleged anti-competitive practices in the country’s soybean seed and biotechnology markets.
CADE Bayer Monsanto: Inside the Superintendence’s Recommendation
The General Superintendence of the Administrative Council for Economic Defense, known as CADE, issued its formal opinion on July 23, 2026. The body recommended that the companies be condemned for practices it deemed harmful to competition.
The investigation focused on two specific alleged infractions. First, offering incentives to plant breeders to adopt the Intacta RR2 PRO biotechnology. Second, using non-linear, loyalty-inducing discounts within Monsanto do Brasil’s Monsoy Multiplica program.
This recommendation stems from complaints made during the original review of German chemicals and pharmaceuticals giant Bayer’s acquisition of US seed maker Monsanto. The deal closed in 2018 but left a lasting regulatory footprint in Brazil.
The Superintendence’s opinion is a critical procedural step, but it is not the final word. The case now moves to the Tribunal of CADE, the agency’s administrative court, which will make the ultimate ruling.
The Billion-Dollar Royalty Battlefield
Parallel to the antitrust case, a massive legal fight over soybean seed royalties continues. The Mato Grosso Soybean and Corn Producers Association, Aprosoja-MT, claims Bayer owes roughly R$10 billion (~US$1.96 billion) in royalties.
This figure is based on an average of R$2 billion (~US$392 million) per year since 2018. The dispute centers on the Intacta RR2 PRO genetically modified seed technology.
Bayer has forcefully rejected a separate claim that a Brazilian court found it liable for about US$2 billion in royalties. The company stated the ruling cited by farmers did not resolve the substance of the dispute.
On February 13, 2023, Brazil’s Supreme Court ordered Bayer to return R$1.3 billion (~US$252 million) in GMO soy royalties to growers, according to Aprosoja-MT. A later court order on July 4 required Monsanto divisions to deposit royalties in escrow.
A New Front: Intacta 2 Xtend
The CADE Superintendence did not limit its scope to past technologies. It also recommended opening a new administrative inquiry into incentives linked to Bayer’s next-generation soybean seeds.
The new probe would examine practices around Intacta 2 Xtend and Xtend technologies. These represent the company’s latest biotech platforms for the crucial Brazilian soy market.
This signals that regulatory scrutiny will follow the company’s product pipeline. It suggests CADE is concerned that the alleged anti-competitive playbook could be replicated with newer products.
Brazil is the world’s largest soybean exporter. The outcome of both the antitrust and royalty cases will shape the business model for agricultural biotechnology across one of the globe’s most vital breadbaskets.
Bayer’s Defense and the Road Ahead
Bayer has consistently denied wrongdoing in both the antitrust and royalty disputes. The company maintains its licensing and commercial practices comply with Brazilian law.
Regarding the royalty claims, Bayer argues that the court rulings cited by farm groups are procedural and do not constitute a final judgment on the merits of the patent dispute.
The company’s position is that its intellectual property rights remain valid and enforceable. The escrow deposit orders are viewed by Bayer as a standard legal measure, not an admission of liability.
With the CADE Tribunal yet to rule, the case could drag on for months or years. The final decision will be closely watched by foreign investors and agribusiness multinationals operating across Latin America.
What This Means for Foreign Investors
For expats and international investors in Brazil’s powerful agricultural sector, the CADE recommendation injects fresh uncertainty. A final condemnation could lead to significant fines and mandated changes to commercial practices.
The case highlights the complex and often contentious regulatory environment for GMO technology in Brazil. Intellectual property enforcement in agriculture remains a high-stakes, legally volatile arena.
Any ruling that weakens biotech royalty collection could reshape investment models for seed innovation. Conversely, a decision upholding the patents would reinforce the value of intellectual property in emerging markets.
For now, all eyes are on the CADE Tribunal. Its decision will provide the clearest signal yet on how Brazil balances competition, innovation, and the economic power of its massive soybean industry.
Frequently Asked Questions
What did CADE’s Superintendence recommend in the Bayer Monsanto case?
On July 23, 2026, the Superintendence recommended condemning and fining Bayer, Monsanto, and related entities for alleged anti-competitive practices, including incentives for Intacta RR2 PRO adoption and loyalty discounts in the Monsoy Multiplica program.
Is the CADE recommendation a final ruling?
No. The recommendation is not final. The case must still be decided by the Tribunal of CADE, the agency’s administrative court, which will issue the binding ruling.
How much does Aprosoja-MT claim Bayer owes in soybean royalties?
The Mato Grosso farmers’ association Aprosoja-MT claims Bayer owes roughly R$10 billion (~US$1.96 billion), based on an average of R$2 billion per year since 2018. Bayer rejects a separate claim of US$2 billion in liability.
Read More from The Rio Times